Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll reiterated an Outperform rating on IGM Biosciences (NASDAQ:IGMS) and maintained a $20 price target.
March 08, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll reiterated an Outperform rating on IGM Biosciences and maintained a $20 price target.
The reiteration of an Outperform rating and maintenance of a $20 price target by a reputable analyst like Robert Driscoll from Wedbush is likely to instill confidence among investors and could positively influence the stock price of IGM Biosciences in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100